Zoll announces approval of next-gen. remedē system

August 5, 2021  –  ZOLL Medical Corporation (Chelmsford, MA), an Asahi Kasei company, announced it has received U.S. Food and Drug Administration (FDA) approval for the remedē EL-X System to treat moderate to severe Central Sleep Apnea (CSA) in adult patients.

The next-generation remedē EL-X System combines enhanced functionality with a patient-friendly design, simplifying the implant procedure and providing greater device longevity for patients with Central Sleep Apnea.

Features of the new device include:

  • Extended longevity: 40% longer average battery life versus previous version
  • Reduced size: Approximately 25% smaller than the previous version
  • Simplified implant: Single lead, single-port system that provides both stimulation and sensing from a single lead
  • Data-driven clinical insights with DRēAM View: Enhancements include full-night, comprehensive diagnostic capabilities

A phased launch of the remedē EL-X System will begin immediately in implanting centers in the U.S.

Learn More

safe online pharmacy for viagra cheap kamagra oral jelly online